シタキセンタン
|
- ￥341300 - ￥757600
- 化學(xué)名: シタキセンタン
- 英語(yǔ)名: N- (4- chloro- 3- methyl- oxazol- 5- yl)- 2- [2- (6- methylbenzo[1,3]dioxol- 5- yl)acetyl]- thiophene- 3- sulfonamide
- 別名:シタキセンタン
- CAS番號(hào): 184036-34-8
- 分子式: C18H15ClN2O6S2
- 分子量: 454.9
- EINECS:
- MDL Number:MFCD00945687
2物価
選択條件：
ブランド
- 富士フイルム和光純薬株式會(huì)社(wako)
パッケージ
- 250mg
- 1g
- 生産者富士フイルム和光純薬株式會(huì)社(wako)
- 製品番號(hào)W01MAS097954
- 製品説明
- 英語(yǔ)製品説明N-(4-Chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d]-[1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide, sodium salt
- 包裝単位250mg
- 価格￥341300
- 更新しました2024-03-01
- 購(gòu)入
- 生産者富士フイルム和光純薬株式會(huì)社(wako)
- 製品番號(hào)W01MAS097954
- 製品説明
- 英語(yǔ)製品説明N-(4-Chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d]-[1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide, sodium salt
- 包裝単位1g
- 価格￥757600
- 更新しました2024-03-01
- 購(gòu)入
| 生産者 | 製品番號(hào) | 製品説明 | 包裝単位 | 価格 | 更新時(shí)間 | 購(gòu)入 |
|---|---|---|---|---|---|---|
| 富士フイルム和光純薬株式會(huì)社(wako) | W01MAS097954 | N-(4-Chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d]-[1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide, sodium salt |
250mg | ￥341300 | 2024-03-01 | 購(gòu)入 |
| 富士フイルム和光純薬株式會(huì)社(wako) | W01MAS097954 | N-(4-Chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d]-[1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide, sodium salt |
1g | ￥757600 | 2024-03-01 | 購(gòu)入 |
プロパティ
融點(diǎn) :42-45°
沸點(diǎn) :663.9±65.0 °C(Predicted)
比重(密度) :1.558
貯蔵溫度 :2-8°C
溶解性 :DMSO
外見 :Powder
酸解離定數(shù)(Pka) :4.96±0.10(Predicted)
沸點(diǎn) :663.9±65.0 °C(Predicted)
比重(密度) :1.558
貯蔵溫度 :2-8°C
溶解性 :DMSO
外見 :Powder
酸解離定數(shù)(Pka) :4.96±0.10(Predicted)
安全情報(bào)
| 絵表示(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| 注意喚起語(yǔ): | ||||||||
| 危険有害性情報(bào): |
|
|||||||
| 注意書き: |
|
説明
Sitaxsentan is a selective endothelin-A (ETA) receptor antagonist launched for the treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity. It is the second ET receptor antagonist to be marketed for this indication behind bosentan. PAH encompasses a heterogeneous group of disorders characterized by inappropriate overactivation of the endothelin system and is characterized by a progressive increase in pulmonary vascular resistance resulting from vascular remodeling, vasoconstriction, and cellular proliferation. Endothelin-1 (ET-1), a potent vasoconstrictor and smooth muscle mitogen, is a key contributor to the acceleration of the disease, and its effects are mediated through activation of ETA and ETB receptors. ETA receptors are found primarily on smooth muscle cells and, when activated, induce vasoconstriction and cellular proliferation. ETB receptors are expressed in both pulmonary vascular endothelial cells and smooth muscle cells, and their activation is associated with the renal and pulmonary clearance of ET.関連商品価格
- N-メチルジエタノールアミン
￥1200-10400 - N-メチルベンゼンカルボアミド
￥6300-222760 - N-メチルベンジルアミン
￥2000-125000